Lv11
40 积分 2025-06-10 加入
A review of sotagliflozin: the first dual SGLT-1/2 inhibitor
5小时前
待确认
Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus
7小时前
已完结
A role for mitochondria in NLRP3 inflammasome activation
2个月前
已完结
SGLT2 Inhibitor Prescribing in Cardiovascular-Kidney-Metabolic Syndrome
4个月前
已完结
Applications of SGLT2 inhibitors beyond glycaemic control
4个月前
已完结
Mineralocorticoid receptor antagonist combined with a SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials
4个月前
已关闭
Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials
4个月前
已关闭
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
4个月前
已完结
Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
4个月前
已完结
皖公网安备34019202002308
